T-cell Acute Lymphoblastic Leukemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Type of Therapy, End User and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: North America
Largest Market: Asia Pacific
CAGR: 7.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • Major factor that is responsible for the growth of T-cell acute lymphoblastic leukaemia market is the rising prevalence of T-cell acute lymphoblastic leukaemia globally.
  • T-cell Acute Lymphoblastic Leukemia Treatment estimated for 15% to 20% of all acute lymphoblastic leukemia by study of the American Society of Clinical Oncology (ASCO). The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that, in 2019, there were around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females.
  • Additionally, growing research and development expenditure on cancer therapeutics, increasing healthcare expenditure and innovations in novel drug development are also propelling the growth of the T-cell acute lymphoblastic leukaemia market globally.
  • However, stringent regulations for the approval of T-ALL drugs, high cost of the treatment and adverse effects associated with therapies are the factors that may hamper the growth of the market.

Scope of the Report

As per the scope, T-cell acute lymphoblastic leukaemia (T-ALL) is a specific type of leukaemia. It is a variant of acute lymphoblastic leukaemia (ALL), with features similar to some types of lymphoma. It affects the lymphoid-cell-producing stem cells, in paticular a type of white blood cell called T lymphocytes whereas ALL usually affects B-lymphocytes. 

By Type of Therapy
Radiation therapy
Stem cell transplant
By End User
Cancer and Radiation Therapy Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy dominate the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

  • The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy drugs are the cell-killing therapeutics. These drugs kill the cancer cells and stop them from dividing.
  • Chemotherapy is normally given as a combination of drugs and for T-ALL, will always include steroids. T-ALL cells is  found in the cerebro spinal fluid (CSF) so chemotherapy for the T-ALL includes injections into CSF. This is called intrathecal chemotherapy. This is more common in T-ALL than in other forms of ALL.
Picture T-ALL market

North America Dominates the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

North America holds a significant market share in the global T-ALL Treatment market and is expected to withstand its position over the forecast period. The diagnosis and prevalence rates of T-ALL is growing rapidly in the region. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

PictureT-cell Acute Lymphoblastic Leukemia Treatment

Competitive Landscape

Currently, many private companies are focusing on the development and introduction of novel therapeutics. Additionally, extensive research and development activities are being initiated by most of the market players, government organizations and academic research institutes. Some of the key innovations in the market are: In 2017, Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration in specific gene, known as Capicua, has been inactivated and that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of T-cell Acute Lymphoblastic Leukemia Market

      2. 4.2.2 Growing Research and Development Expenditure on Cancer Therapeutics

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Scenario for the Drug Approvals

      2. 4.3.2 High Cost Asscoiated with the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type of Therapy

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Radiation therapy

      3. 5.1.3 Stem cell transplant

      4. 5.1.4 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Cancer and Radiation Therapy Centers

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Bristol Myer Squibb Company

      2. 6.1.2 Celegene Corporation

      3. 6.1.3 Kyowa Kirin Co., Ltd.

      4. 6.1.4 Erytech Pharma

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Genmab AS

      7. 6.1.7 GlaxoSmithKline

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Spectrum Pharmaceuticals

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The T-cell Acute Lymphoblastic Leukemia Treatment Market market is studied from 2018 - 2026.

The T-cell Acute Lymphoblastic Leukemia Treatment Market is growing at a CAGR of 7.8% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2020.

Bristol Myer Squibb Company, Genmab A/S, Novartis AG, Pfizer Inc., Kyowa Kirin Co., Ltd. are the major companies operating in T-cell Acute Lymphoblastic Leukemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!